[Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
A prospective randomized study of 195 patients with endometrial cancer, who were treated by adjuvant hormone therapy, is reported. 100 patients received 100 mg medroxyprogesterone acetate alone, 95 a combination of medroxyprogesterone acetate and tamoxifen (2 x 10 mg). Our data show no statistical difference between the two groups.
Vavra
N
N
I. Universitäts-Frauenklinik, Wien, Osterreich.
Salzer
H
H
Sevelda
P
P
Breitenecker
G
G
Czerwenka
K
K
Kucera
H
H
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D011446:Prospective Studies; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D013629:Tamoxifen; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone
Adjuvante Hormontherapie beim Endometriumkarzinom: Medroxyprogesteronazetat- versus Tamoxifen-Medroxyprogesteronazetat-Sequenztherapie.